Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...
Study findings provide new tools to assess treatment preferences when using hypomethylating agents in myelodysplastic syndromes (MDS). The study aimed to develop the TPMQ for clinicians (mTPMQ), ...
Social worker Marie Brewer talks about the challenges of supporting a loved one with myelodysplastic syndrome (MDS) and ways to find assistance and treatment options. Myelodysplastic syndromes (MDS) ...
Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...
The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic syndromes (MDS). However, most of what scientists know about the impact of ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
(WASHINGTON – August 6, 2025) – Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results ...
Younger patients with relapsed MDS may benefit from DLI post-stem cell transplant, improving overall survival rates. DLI is associated with graft-versus-host disease, but its impact on prognosis is ...
Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The ...
“The success of the SELECT-MDS-1 trial was as an efficiently accrued international phase 3 trial that was biomarker driven, the first of its kind in MDS. Although the doublet combination tested in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results